Isoxaben

CASRN 82558-50-7

  • IRIS Summary (PDF) (12 pp, 110 K)
  • Status: Isoxaben is not being reassessed by IRIS at this time.

Health Hazard Assessments for Effects Other than Cancer


Reference Dose for Oral Exposure (RfD) (PDF) (12 pp, 110 K) last updated: 09/26/1988

RfD (mg/kg-day) System Basis PoD Composite UF Confidence
5 x10-2 Hepatic, Urinary, Cardiovascular Increased BUN; decreased serum AP and AST; decreased food consumption efficiency; increased heart/body weight NOEL : 5
mg/kg-day
100 High

Reference Concentration for Inhalation Exposure (RfC) (PDF) (12 pp, 110 K)
Not assessed under the IRIS Program.

Cancer Assessment


Weight of Evidence for Cancer (PDF) (12 pp, 110 K) last updated: 09/01/1991

WOE Characterization Framework for WOE Characterization
C (Possible human carcinogen) Guidelines for Carcinogen Risk Assessment (US EPA, 1986)
Basis:
  • Based on a statistically significant increased incidence of benign liver tumors in one species.
  • This may be a synopsis of the full weight-of-evidence narrative.

Quantitative Estimate of Carcinogenic Risk from Oral Exposure (PDF) (12 pp, 110 K)

Not assessed under the IRIS Program.

Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure (PDF) (12 pp, 110 K)

Not assessed under the IRIS Program.

You will need Adobe Reader to view some of the files on this page. See EPA’s PDF page to learn more.